Top Biotech companies in Boston

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause. The Company develops medicines for previously untreatable or undertreated diseases and provides meaningful support for healthcare providers and patients and their families. In addition to commercializing its lead asset in North America, Europe and other regions, Rhythm is advancing a broad clinical development program in rare MC4R pathway diseases, as well as investigational MC4R agonists, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.At Rhythm, we know our work makes an important difference in the lives of patients and their families around the world. Every employee contributes to the company’s goal of discovering new treatments for rare diseases that no other company is developing. As a fast-growing company with an exciting future, we offer a collaborative environment where employees’ contributions truly matter, which is one of the many reasons we were recognized as one of The Boston Globe’s Top Places to Work in Massachusetts for 2023 and 2024.

• Post-IPO equity
• 475 employees
• Founded 2008

Velsera was formed in 2023 through the shared vision of Seven Bridges and Pierian, with a mission to accelerate the discovery, development, and delivery of life-changing insights. Velsera provides software and professional services for:• Multimodal Data Harmonization & Analytics for Drug Discovery & Development• IVD Development, Validation & Approval• Clinical NGS Interpretation, Reporting & AdoptionJoin our community (support.velsera.com/hc/en-us/community/topics) and explore our solutions (velsersa.com/solutions).Let's drive the future of precision medicine - together.

• 422 employees
• Founded 2023

Nucleate is a free, trainee-led 501(c)(3) non-profit organization dedicated to empowering the next generation of biotech leaders. As a global organization, we democratize biotech education, spark new intellectual communities, and build bridges within and across ecosystems by providing open-access programming, events and resources.

• 407 employees
• Founded 2019

The Wyss Institute at Harvard University is a nonprofit research organization dedicated to translating groundbreaking discoveries from the lab into real-world solutions for human and planetary health. Since its founding in 2009, the Wyss has created a powerful pipeline of breakthrough technologies – from advanced diagnostics and novel therapies to sustainable engineering solutions – by leveraging Nature’s genius to tackle urgent global challenges. Through a unique model of radical collaboration across disciplines and a relentless focus on impact, the Wyss brings together scientists, engineers, clinicians, and industry leaders to accelerate innovations that improve lives and our environment.

• Seed
• 380 employees
• Founded 2009

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

• Post-IPO debt
• 342 employees
• Founded 2013